

---

# Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies

Boni E. Elewski, MD,<sup>a</sup> Raza Aly, PhD,<sup>b</sup> Sheryl L. Baldwin, RN,<sup>c</sup> Remigio F. González Soto, MD,<sup>d</sup> Phoebe Rich, MD,<sup>e</sup> Max Weisfeld, DPM,<sup>f</sup> Hector Wiltz, MD, CPI,<sup>g</sup> Lee T. Zane, MD,<sup>d</sup> and Richard Pollak, DPM, MS<sup>h</sup>  
*Birmingham, Alabama; San Francisco and Palo Alto, California; Monterrey, Mexico; Portland, Oregon; Baltimore, Maryland; Miami, Florida; and San Antonio, Texas*

**Background:** Onychomycosis, a fungal nail infection, can impact quality of life.

**Objective:** We sought to evaluate the efficacy and safety of tavaborole topical solution, 5% for treatment of toenail onychomycosis.

**Methods:** In 2 phase-III trials, adults with distal subungual onychomycosis affecting 20% to 60% of a target great toenail were randomized 2:1 to tavaborole or vehicle once daily for 48 weeks. The primary end point was complete cure of the target great toenail (completely clear nail with negative mycology) at week 52. Secondary end points included completely or almost clear nail, negative mycology, completely or almost clear nail plus negative mycology, and safety.

**Results:** Rates of negative mycology (31.1%-35.9% vs 7.2%-12.2%) and complete cure (6.5% and 9.1% vs 0.5% and 1.5%) significantly favored tavaborole versus vehicle ( $P \leq .001$ ). Completely or almost clear nail rates also significantly favored tavaborole versus vehicle (26.1%-27.5% vs 9.3%-14.6%;  $P < .001$ ). Rates of completely or almost clear nail plus negative mycology (15.3%-17.9% vs 1.5%-3.9%) were significantly greater for tavaborole versus vehicle ( $P < .001$ ). Application-site reactions with tavaborole included exfoliation (2.7%), erythema (1.6%), and dermatitis (1.3%).

**Limitations:** Duration of follow-up is a limitation.

---

From the Department of Dermatology, University of Alabama at Birmingham<sup>a</sup>; Department of Dermatology, University of California, San Francisco<sup>b</sup>; Anacor Pharmaceuticals, Inc, Palo Alto<sup>c</sup>; Centro de Dermatología de Monterrey<sup>d</sup>; Oregon Health and Science University<sup>e</sup>; Hamilton Foot Care, Baltimore<sup>f</sup>; FXM Research Corp, Miami<sup>g</sup>; and Endeavor Clinical Trials, San Antonio.<sup>h</sup>

Writing and editorial assistance was provided by Callie Grimes of Peloton Advantage, LLC, Parsippany, NJ, and was supported by Anacor Pharmaceuticals, Inc. Diane Nelson of Anacor Pharmaceuticals, Inc, provided critical review and revision of the manuscript.

Disclosure: Ms Baldwin and Dr Zane are employees of Anacor Pharmaceuticals, Inc. Dr Elewski has received honoraria and grants while serving as a consultant and investigator with the following companies: Anacor Pharmaceuticals, Inc; Valeant Pharmaceuticals International Inc, Bridgewater, NJ; and Meiji Seika Pharma Co, Ltd, Tokyo, Japan. Dr Aly was consultant and investigator for Anacor Pharmaceuticals, Inc. Dr González Soto was an investigator for the following companies: Anacor Pharmaceuticals, Inc; Pfizer, New York, NY; and Eli Lilly, Indianapolis, IN. Dr Rich was the principal investigator for

---

Pharmaceuticals, Inc; Topica Pharmaceuticals, Los Altos, CA; Valeant Pharmaceuticals International Inc; and Viamet Pharmaceuticals Inc, Durham, NC. Dr Pollak has received grants and honoraria while serving as advisory board member, investigator, and speaker for the following companies: Anacor Pharmaceuticals, Inc; Valeant Pharmaceuticals International Inc; and Topica Pharmaceuticals. Drs Weisfeld and Wiltz were principal investigators for Anacor Pharmaceuticals, Inc. The authors were fully responsible for the content, editorial decisions, and opinions expressed in the current article. No author received an honorarium related to the development of this manuscript.

Accepted for publication April 6, 2015.

Reprint requests: Boni E. Elewski, MD, Department of Dermatology, University of Alabama at Birmingham, EFH 414, 1530 3rd Ave S, Birmingham, AL 35294-0009. E-mail: [beelewski@aol.com](mailto:beelewski@aol.com).

Published online May 5, 2015.

0190-9622

© 2015 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<http://dx.doi.org/10.1016/j.jaad.2015.04.010>

**Conclusion:** Tavaborole demonstrates a favorable benefit-risk profile in treatment of toenail onychomycosis. (J Am Acad Dermatol 2015;73:62-9.)

**Key words:** antifungal agents; arthrodermataceae; nails; onychomycosis; randomized controlled trial; tavaborole.

Tavaborole topical solution, 5% (Anacor Pharmaceuticals, Inc, Palo Alto, CA) is a novel, boron-based pharmaceutical approved by the Food and Drug Administration (FDA) in July 2014 for the treatment of toenail onychomycosis caused by *Trichophyton rubrum* and *T mentagrophytes*.<sup>1</sup> Tavaborole represents a new class of pharmaceutical antifungal agents with a novel chemical structure and mechanism of action (Fig 1).<sup>2-5</sup> Tavaborole targets fungal cytoplasmic leucyl-transfer ribonucleic acid (tRNA) synthetase, a member of a family of aminoacyl-tRNA synthetase enzymes essential for protein synthesis.<sup>5</sup> These enzymes maintain and translate genetic code within DNA, and possess a proofreading mechanism that corrects enzymatic mistakes that occur on a separate, active editing site. Tavaborole binds to the editing site via its boron atom to trap leucyl tRNA, preventing its catalytic turnover and inhibiting protein synthesis. Tavaborole demonstrates broad-spectrum antifungal activity and more than 1000-fold greater selectivity for the fungal leucyl-tRNA synthetase than the mammalian leucyl-tRNA synthetase<sup>6</sup>; *T rubrum* and *T mentagrophytes* isolates collected from clinical trial patients have not demonstrated resistance after repeated exposure to tavaborole.<sup>1</sup>

The low molecular weight of tavaborole allows a high amount of penetration through full-thickness human nail plates.<sup>7</sup> Ex vivo permeation studies have demonstrated tavaborole penetration through multiple layers of nail polish (data on file, Anacor Pharmaceuticals, Inc; TER-002-14, ANA-005, 2013). Phase-I trials showed favorable safety and low systemic exposure in patients with toenail onychomycosis,<sup>8</sup> and phase-II trials provided evidence of improved clear nail growth and negative fungal cultures.<sup>9</sup> The objective of the 2 phase-III trials described herein was to evaluate the efficacy and safety of tavaborole versus vehicle in adults with distal subungual toenail onychomycosis.

## CAPSULE SUMMARY

- Tavaborole topical solution, 5% is approved for treatment of toenail onychomycosis.
- Tavaborole was significantly more effective than vehicle in treating toenail onychomycosis in 2 phase-III trials; incidence of treatment-related application-site reactions was low.
- The favorable benefit-risk profile makes tavaborole a reasonable therapeutic option for toenail onychomycosis.

## METHODS

### Study treatment and patients

Study treatments included tavaborole and vehicle, which were applied topically to the affected nails once daily for 48 weeks by the patient. Patients were instructed to apply a sufficient amount of study treatment on, under, and around the infected target great toenail (TGT) and infected nontarget toenails with a thin, even layer.

Patients 18 years of age or older with distal subungual toenail onychomycosis involving 20% to 60% of at least 1 TGT were eligible if they had a positive potassium hydroxide (KOH) wet mount and positive culture for dermatophytes, greater than or equal to 3-mm clear nail measured from the proximal nail fold to the most proximal visible mycotic border, and distal TGT thickness 3 mm or less. Patients were excluded if they had proximal subungual or superficial white onychomycosis, severe disease, dermatophytoma, exclusively lateral disease, yellow/brown spikes, coinfection with nondermatophyte fungi, anatomic abnormalities of the toes or toenails, active tinea pedis (involving the sides or back of the foot, interdigital, or plantar) requiring treatment, history of chronic moccasin-type tinea pedis (involving the sides or back of the foot), history of other significant chronic fungal disease, psoriasis, lichen planus, known immunodeficiency, significant peripheral vascular disease, known structural heart disease, or uncontrolled diabetes (hemoglobin A1C  $\geq$ 8%). Patients who used topical antifungals on the toenails within 4 weeks or systemic antifungals within 24 weeks were also excluded. Recent use of other topical agents on the toe or toenails, systemic corticosteroids, or immunomodulatory agents was not permitted.

### Study design

Two phase-III, multicenter, randomized, double-blind, vehicle-controlled, parallel-group trials of

**Abbreviations used:**

AE:	adverse event
FDA:	Food and Drug Administration
KOH:	potassium hydroxide
TEAE:	treatment-emergent adverse event
TGT:	target great toenail
tRNA:	transfer ribonucleic acid


identical design were conducted: 1 at 27 sites in the United States and Mexico from December 2010 to November 2012 (study 1; NCT01270971) and the other at 32 sites in the United States and Canada from February 2011 to January 2013 (study 2; NCT01302119). Both studies were conducted in accordance with ethical principles originating in the Declaration of Helsinki and in compliance with the principles of Good Clinical Practice and all applicable regulatory requirements. The study protocol was approved by an institutional review board/independent ethics committee at each site, and all patients provided written informed consent.

Patients were screened 4 to 10 weeks before randomization. Eligible patients were randomized 2:1 to receive tavaborole or vehicle, and applied study treatment to the TGT and all other affected toenails once daily for 48 weeks. Nail debridement was not permitted.

Disease involvement was assessed at screening, baseline (day 1), week 2, week 6, and every 6 weeks thereafter. At these visits, nail trimming of the TGT was limited to within 1 mm distal to the hyponychium or distal groove if needed. Patients were encouraged not to trim the TGT. All other toenails were also evaluated for the presence of onycholysis and subungual hyperkeratosis. Subungual samples were obtained from the TGT at screening and every 12 weeks during treatment and sent to a central mycology laboratory for KOH wet mount examination with calcofluor white stain and fungal culture to identify pathogenic fungi including dermatophyte species. After study treatment was completed at week 48, follow-up efficacy assessments were made at week 52.

**Efficacy**

The primary efficacy end point was complete cure of the TGT defined as completely clear nail and negative mycology at week 52. Secondary end points included completely or almost clear nail of the TGT, negative mycology of the TGT, and completely or almost clear nail plus negative mycology, each determined at week 52. Completely clear nail was defined as no clinical evidence of onychomycosis

**Tavaborole**

**Fig 1.** Tavaborole chemical structure. Tavaborole is a novel, boron-based pharmaceutical approved for the treatment of toenail onychomycosis caused by *Trichophyton rubrum* and *T mentagrophytes*.<sup>1</sup> Tavaborole inhibits leucyl-tRNA-synthetase, resulting in inhibition of fungal protein synthesis and termination of fungal cell growth.<sup>5</sup>

no subungual hyperkeratosis. Almost clear nail was defined as no more than minimal evidence of onychomycosis based on a toenail plate that was dystrophic or discolored on 10% or less of the distal aspect, with minimally evident onycholysis and subungual hyperkeratosis. Negative mycology was defined as negative KOH wet mount and negative fungal culture.

**Safety**

Safety assessments were conducted at each visit, as was a physical examination evaluating the frequency and severity of application-site reactions: burning/stinging, induration/edema, oozing/crusting, pruritus, erythema, and scaling. Adverse events (AEs), treatment-emergent AEs (TEAEs), serious AEs, vital signs, laboratory parameters, and electrocardiographic parameters were monitored throughout the study.

**Statistics**

Efficacy parameters were evaluated in the intent-to-treat population, which included all randomized patients who received study treatment. Safety parameters were evaluated in all randomized patients who received at least 1 dose of study treatment and had at least 1 postbaseline assessment. Comparisons between treatment groups for the primary and secondary efficacy end points were made using the Cochran-Mantel-Haenszel test stratified by analysis. A last-observation-carried-forward approach was used to impute missing efficacy data. Two-sided hypothesis testing was conducted using a significance level of .05. AEs were classified using the Medical Dictionary for




Fig 2. Toenail onychomycosis. Patient disposition. *ITT*, Intent-to-treat.

*Regulatory Activities* (Version 13.1, <http://www.meddra.org>). All safety parameters were summarized descriptively by treatment group.

## RESULTS

### Patients

The disposition of patients (study 1, N = 594; study 2, N = 604) is depicted in Fig 2. Demographic and clinical characteristics of the intent-to-treat population were similar between treatment groups and generally consistent across the 2 trials (Table I).

### Efficacy

Tavaborole was significantly more effective than vehicle for all primary and secondary efficacy end points, and produced higher rates of negative culture and negative KOH at week 52 versus vehicle (Table II). A significantly greater proportion of patients achieved complete cure of the TGT at week 52 with tavaborole versus vehicle in study 1 (6.5% vs 0.5%;  $P = .001$ ) and study 2 (9.1% vs 1.5%;  $P < .001$ ). Rates of completely or almost clear nail at week 52 with tavaborole were 26.1% and 27.5% in study 1 and study 2, respectively, versus 9.3% and 14.6% with vehicle (study 1,  $P < .001$ ; study 2,  $P < .001$ ).

with tavaborole were 31.1% and 35.9% in study 1 and study 2, respectively, versus 7.2% and 12.2% with vehicle (both  $P < .001$ ). Photographs illustrating a case with complete cure and a case of almost clear nail with negative mycology are shown in Fig 3.

The onset of tavaborole clinical activity was evident by week 24 and generally increased through the end of treatment at week 48 and the final efficacy assessment at week 52 (Fig 4). Complete cure of the TGT was observed as early as week 24 in study 2 and at week 30 in study 1. Negative culture rates ranged from 95% at week 24 to 87% at week 52 in study 1 and 94% at week 24 to 85% at week 52 in study 2. Negative KOH rates mirrored negative mycology data.

### Safety

The incidence of TEAEs with tavaborole versus vehicle was similar in study 1 (64.4% vs 69.9%, respectively) and study 2 (57.5% vs 54.0%, respectively) (Table III). Most TEAEs in patients receiving tavaborole (95.5%) or vehicle (93.4%) were reported as mild or moderate in severity. The most common treatment-related application site TEAE with tavaborole in the 2 trials combined

**Table I.** Demographics and baseline characteristics of the intent-to-treat population

Characteristic	Study 1		Study 2	
	Tavaborole (n = 399)	Vehicle (n = 194)	Tavaborole (n = 396)	Vehicle (n = 205)
Age, y				
Mean (SD)	53.6 (12.5)	53.4 (12.3)	55.5 (11.5)	55.4 (11.0)
Range	18-88	19-81	20-81	27-81
Gender, n (%)				
Male	324 (81.2)	158 (81.4)	323 (81.6)	174 (84.9)
Female	75 (18.8)	36 (18.6)	73 (18.4)	31 (15.1)
Race				
White	316 (79.2)	152 (78.4)	355 (89.6)	183 (89.3)
Black	19 (4.8)	12 (6.2)	21 (5.3)	14 (6.8)
American Indian/Alaska Native	0 (0)	0 (0)	2 (0.5)	1 (0.5)
Asian	2 (0.5)	0 (0)	11 (2.8)	2 (1.0)
Native Hawaiian/Pacific Islander	0 (0)	0 (0)	2 (0.5)	1 (0.5)
Other	62 (15.5)	30 (15.5)	5 (1.3)	4 (2.0)
Country				
United States	340 (85.2)	164 (84.5)	315 (79.5)	165 (80.5)
Canada	—	—	81 (20.5)	40 (19.5)
Mexico	59 (14.8)	30 (15.5)	—	—
No. of nontarget toenails $\geq 10\%$ affected by onychomycosis				
Mean (SD)	3.4 (2.8)	3.8 (2.7)	3.3 (2.8)	3.3 (2.6)
Range	0-9	0-9	0-9	0-9

**Table II.** Efficacy end points at week 52

End point	Study 1			Study 2		
	Tavaborole (n = 399) n (%)	Vehicle (n = 194) n (%)	P value	Tavaborole (n = 396) n (%)	Vehicle (n = 205) n (%)	P value
Primary end point						
Complete cure of TGT*	26 (6.5)	1 (0.5)	.001	36 (9.1)	3 (1.5)	<.001
Secondary end points						
Completely CN or almost CN of TGT	104 (26.1)	18 (9.3)	<.001	109 (27.5)	30 (14.6)	<.001
Negative mycology of TGT	124 (31.1)	14 (7.2)	<.001	142 (35.9)	25 (12.2)	<.001
Completely or almost CN plus negative mycology of the TGT	61 (15.3)	3 (1.5)	<.001	71 (17.9)	8 (3.9)	<.001
Other end points						
Negative culture of TGT	347 (87.0)	93 (47.9)	—	338 (85.4)	105 (51.2)	—
Negative KOH of TGT	128 (32.1)	17 (8.8)	—	147 (37.1)	35 (17.1)	—
Completely CN or almost CN of TGT with negative culture	98 (24.6)	11 (5.7)	—	100 (25.3)	19 (9.3)	—

CN, Clear nail; KOH, potassium hydroxide wet mount; TGT, target great toenail.

\*Completely CN and negative mycology.

were exfoliation (2.7%), erythema (1.6%), and dermatitis (1.3%). The majority of TEAEs were considered not related or unlikely related to study treatment. The incidence of treatment-related TEAEs was higher with tavaborole versus vehicle in study 1 (8.8% vs 2.6%, respectively) and study 2 (3.3% vs 0.5%, respectively) and was attributed to a higher rate of application-site reactions with tavaborole versus vehicle in study 1 (7.3% vs 0.5%,

respectively) and study 2 (3.0% vs 0%, respectively). Rates of discontinuations as a result of AEs occurred at similar rates between treatment groups (Table III).

There were no deaths in either study. Serious AEs were reported in 19 patients (2.4%) who received tavaborole and 10 patients (2.5%) who received vehicle; none were considered treatment-related. Results of clinical laboratory and vital assessments

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.